DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants

Phase 1

Completed

Conditions: Electrocardiography

Interventions: Drug: Avacopan
Drug: Moxifloxacin
Drug: Placebo for avacopan
Drug: Placebo for moxifloxacin

First Posted Date: 2023-08-14

Last Posted Date: 2023-08-14

Lead Sponsor: Amgen

Target Recruit Count: 58

Registration Number: NCT05988034

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168

Phase 1

Completed

Conditions: Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Interventions: Drug: CCX168

First Posted Date: 2023-08-14

Last Posted Date: 2023-08-14

Lead Sponsor: Amgen

Target Recruit Count: 16

Registration Number: NCT05988021

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants

Phase 1

Completed

Conditions: Vasculitis
Systemic Lupus Erythematosus (SLE)

Interventions: Drug: CCX168
Drug: Placebo

First Posted Date: 2023-08-09

Last Posted Date: 2023-08-09

Lead Sponsor: Amgen

Target Recruit Count: 48

Registration Number: NCT05984251

Locations: 🇨🇭
Covance Clinical Research Unit (CRU) AG, Allschwil, Switzerland

A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Phase 1

Active, not recruiting

Conditions: MTAP-null Non-Small-Cell Lung Cancer
MTAP-null Solid Tumors

Interventions: Drug: AMG 193
Drug: IDE397

First Posted Date: 2023-08-03

Last Posted Date: 2025-02-27

Lead Sponsor: Amgen

Target Recruit Count: 53

Registration Number: NCT05975073

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇺🇸
Astera Cancer Care, East Brunswick, New Jersey, United States
🇪🇸
Hospital Universitari Vall d Hebron, Barcelona, Cataluña, Spain

and more 24 locations

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

Phase 3

Recruiting

Conditions: Osteogenesis Imperfecta

Interventions: Drug: Bisphosphonate
Drug: Romosozumab

First Posted Date: 2023-08-02

Last Posted Date: 2025-03-13

Lead Sponsor: Amgen

Target Recruit Count: 106

Registration Number: NCT05972551

Locations: 🇭🇺
Semmelweis Egyetem, Budapest, Hungary
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 35 locations

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Phase 3

Recruiting

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Sotorasib
Drug: Pembrolizumab

First Posted Date: 2023-06-27

Last Posted Date: 2025-05-22

Lead Sponsor: Amgen

Target Recruit Count: 750

Registration Number: NCT05920356

Locations: 🇺🇸
Sansum Clinic, Santa Barbara, California, United States
🇺🇸
University of Illinois Chicago, Chicago, Illinois, United States
🇺🇸
Illinois Cancer Specialists, Niles, Illinois, United States

and more 356 locations

A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer

Phase 1

Completed

Conditions: Gastric or Gastroesophageal Cancer

Interventions: Drug: FPA144

First Posted Date: 2023-06-22

Last Posted Date: 2023-06-22

Lead Sponsor: Amgen

Target Recruit Count: 6

Registration Number: NCT05913115

Locations: 🇯🇵
St Marianna University Hospital, Kawasaki-shi, Kanagawa, Japan
🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants

Phase 1

Completed

Conditions: Adalimumab

Interventions: Drug: ABP 501-LCF
Drug: ABP 501-HCF

First Posted Date: 2023-06-18

Last Posted Date: 2023-06-18

Lead Sponsor: Amgen

Target Recruit Count: 372

Registration Number: NCT05909852

Locations: 🇺🇸
WCCT Global, Inc, Cypress, California, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
Pharmaceutical Research Associates, Inc, Salt Lake City, Utah, United States

Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

Recruiting

Conditions: Neuromyelitis Optica Spectrum Disorder
Pregnancy Related

First Posted Date: 2023-06-18

Last Posted Date: 2025-02-19

Lead Sponsor: Amgen

Target Recruit Count: 60

Registration Number: NCT05909761

Locations: 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

Phase 3

Completed

Conditions: Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis

Interventions: Drug: Placebo
Drug: Rocatinlimab

First Posted Date: 2023-06-12

Last Posted Date: 2025-02-07

Lead Sponsor: Amgen

Target Recruit Count: 221

Registration Number: NCT05899816

Locations: 🇺🇸
Affiliated Dermatology, Scottsdale, Arizona, United States
🇺🇸
Center for Dermatology and Plastic Surgery, Scottsdale, Arizona, United States
🇺🇸
Scottsdale Clinical Trials, Scottsdale, Arizona, United States

and more 82 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy